Alan M Jacobson1, Christopher M Ryan2, Barbara H Braffett3, Rose A Gubitosi-Klug4, Gayle M Lorenzi5, José A Luchsinger6, Victoria R Trapani3, Ionut Bebu3, Naomi Chaytor7, Susan M Hitt8, Kaleigh Farrell4, John M Lachin3. 1. NYU Long Island School of Medicine, NYU Langone Hospital-Long Island, Mineola, NY, USA. Electronic address: alan.jacobson@nyulangone.org. 2. University of Pittsburgh, Pittsburgh, PA, USA. 3. George Washington University, Biostatistics Center, Rockville, MD, USA. 4. Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, OH, USA. 5. University of California San Diego, La Jolla, CA, USA. 6. Columbia University Irving Medical Center, New York, NY, USA. 7. Elson S Floyd College of Medicine, Washington State University, Spokane, WA, USA. 8. Columbia School of Medicine, University of Missouri, Columbia, MO, USA.
Abstract
BACKGROUND: With improved treatment, individuals with type 1 diabetes are living longer but there is limited information on the effects of type 1 diabetes on cognitive ability as they become older adults. We followed up individuals with type 1 diabetes to identify independent risk factors for cognitive decline as people age. METHODS: 1051 participants with type 1 diabetes enrolled in the Diabetes Control and Complications Trial (DCCT) and its follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study. Participants completed cognitive assessments at baseline (median age 27 years) and 2, 5, 18, and 32 years later (median age 59). HbA1c levels, frequency of severe hypoglycaemia, non-glycemic risk factors such as elevated blood pressure, and microvascular and macrovascular complications were assessed repeatedly. We examined the effects of these on measures of memory and psychomotor and mental efficiency. These studies are registered with clinicaltrials.gov, NCT00360815 (DCCT) and NCT00360893 (EDIC). FINDINGS: Over 32 years of follow-up, we found substantive declines in memory and psychomotor and mental efficiency. Between 18 and 32 years of follow-up, the decline in psychomotor and mental efficiency was five times larger than the change from baseline to year 18. Independent of the other risk factors and comorbidities, exposure to higher HbA1c levels, more episodes of severe hypoglycaemia, and elevated systolic blood pressure were associated with greater decrements in psychomotor and mental efficiency that was most notable by year 32 (p<0·0001). The combined effect of the presence of these three risk factors is the equivalent to an additional 9·4 years of age. INTERPRETATION: Cognitive function declines with ageing in type 1 diabetes. The association of glycaemia and blood pressure levels with cognitive decline suggests that better management might preserve cognitive function. FUNDING: United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease.
BACKGROUND: With improved treatment, individuals with type 1 diabetes are living longer but there is limited information on the effects of type 1 diabetes on cognitive ability as they become older adults. We followed up individuals with type 1 diabetes to identify independent risk factors for cognitive decline as people age. METHODS: 1051 participants with type 1 diabetes enrolled in the Diabetes Control and Complications Trial (DCCT) and its follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study. Participants completed cognitive assessments at baseline (median age 27 years) and 2, 5, 18, and 32 years later (median age 59). HbA1c levels, frequency of severe hypoglycaemia, non-glycemic risk factors such as elevated blood pressure, and microvascular and macrovascular complications were assessed repeatedly. We examined the effects of these on measures of memory and psychomotor and mental efficiency. These studies are registered with clinicaltrials.gov, NCT00360815 (DCCT) and NCT00360893 (EDIC). FINDINGS: Over 32 years of follow-up, we found substantive declines in memory and psychomotor and mental efficiency. Between 18 and 32 years of follow-up, the decline in psychomotor and mental efficiency was five times larger than the change from baseline to year 18. Independent of the other risk factors and comorbidities, exposure to higher HbA1c levels, more episodes of severe hypoglycaemia, and elevated systolic blood pressure were associated with greater decrements in psychomotor and mental efficiency that was most notable by year 32 (p<0·0001). The combined effect of the presence of these three risk factors is the equivalent to an additional 9·4 years of age. INTERPRETATION: Cognitive function declines with ageing in type 1 diabetes. The association of glycaemia and blood pressure levels with cognitive decline suggests that better management might preserve cognitive function. FUNDING: United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease.
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Ruth S Weinstock; Stephanie N DuBose; Richard M Bergenstal; Naomi S Chaytor; Christina Peterson; Beth A Olson; Medha N Munshi; Alysa J S Perrin; Kellee M Miller; Roy W Beck; David R Liljenquist; Grazia Aleppo; John B Buse; Davida Kruger; Anuj Bhargava; Robin S Goland; Rachel C Edelen; Richard E Pratley; Anne L Peters; Henry Rodriguez; Andrew J Ahmann; John-Paul Lock; Satish K Garg; Michael R Rickels; Irl B Hirsch Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Virginia G Wadley; Tyler P Bull; Yue Zhang; Cheyanne Barba; R Nick Bryan; Michael Crowe; Lisa Desiderio; Georg Deutsch; Guray Erus; David S Geldmacher; Rodney Go; Caroline L Lassen-Greene; Olga A Mamaeva; Daniel C Marson; Marianne McLaughlin; Ilya M Nasrallah; Cynthia Owsley; Jesse Passler; Rodney T Perry; Giovanna Pilonieta; Kayla A Steward; Richard E Kennedy Journal: J Gerontol A Biol Sci Med Sci Date: 2021-09-13 Impact factor: 6.053
Authors: Karen A Nunley; Caterina Rosano; Christopher M Ryan; J Richard Jennings; Howard J Aizenstein; Janice C Zgibor; Tina Costacou; Robert M Boudreau; Rachel Miller; Trevor J Orchard; Judith A Saxton Journal: Diabetes Care Date: 2015-07-07 Impact factor: 19.112
Authors: Tandy Aye; Paul K Mazaika; Nelly Mauras; Matthew J Marzelli; Hanyang Shen; Tamara Hershey; Allison Cato; Stuart A Weinzimer; Neil H White; Eva Tsalikian; Booil Jo; Allan L Reiss Journal: Diabetes Care Date: 2018-12-20 Impact factor: 19.112
Authors: Richard I G Holt; J Hans DeVries; Amy Hess-Fischl; Irl B Hirsch; M Sue Kirkman; Tomasz Klupa; Barbara Ludwig; Kirsten Nørgaard; Jeremy Pettus; Eric Renard; Jay S Skyler; Frank J Snoek; Ruth S Weinstock; Anne L Peters Journal: Diabetologia Date: 2021-12 Impact factor: 10.122
Authors: Alan M Jacobson; Barbara H Braffett; Guray Erus; Christopher M Ryan; Geert J Biessels; José A Luchsinger; Ionut Bebu; Rose A Gubitosi-Klug; Lisa Desiderio; Gayle M Lorenzi; Victoria R Trapani; John M Lachin; R Nick Bryan; Mohamad Habes; Ilya M Nasrallah Journal: Diabetes Care Date: 2022-08-01 Impact factor: 17.152
Authors: Ioannis Bakolis; Nicole de Zoysa; Stephanie A Amiel; Laura Potts; Kimberley Goldsmith; Peter Jacob; Emma L Smith; Linda Gonder-Frederick; Simon Heller; Elena Toschi; Augustin Brooks; Dulmini Kariyawasam; Pratik Choudhary; Marietta Stadler; Helen Rogers; Mike Kendall; Nick Sevdalis Journal: Nat Commun Date: 2022-04-28 Impact factor: 17.694